Crinetics Pharmaceuticals Statistics
Total Valuation
CRNX has a market cap or net worth of $4.13 billion. The enterprise value is $3.09 billion.
Important Dates
The last earnings date was Thursday, November 6, 2025, after market close.
| Earnings Date | Nov 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CRNX has 94.89 million shares outstanding. The number of shares has increased by 24.75% in one year.
| Current Share Class | 94.89M |
| Shares Outstanding | 94.89M |
| Shares Change (YoY) | +24.75% |
| Shares Change (QoQ) | +0.45% |
| Owned by Insiders (%) | 1.46% |
| Owned by Institutions (%) | 108.96% |
| Float | 87.74M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2,690.35 |
| Forward PS | 125.81 |
| PB Ratio | 3.84 |
| P/TBV Ratio | 3.85 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2,010.78 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 15.12, with a Debt / Equity ratio of 0.05.
| Current Ratio | 15.12 |
| Quick Ratio | 14.73 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -44.42% and return on invested capital (ROIC) is -29.76%.
| Return on Equity (ROE) | -44.42% |
| Return on Assets (ROA) | -28.00% |
| Return on Invested Capital (ROIC) | -29.76% |
| Return on Capital Employed (ROCE) | -42.59% |
| Revenue Per Employee | $3,513 |
| Profits Per Employee | -$968,185 |
| Employee Count | 437 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -20.47% in the last 52 weeks. The beta is 0.20, so CRNX's price volatility has been lower than the market average.
| Beta (5Y) | 0.20 |
| 52-Week Price Change | -20.47% |
| 50-Day Moving Average | 40.63 |
| 200-Day Moving Average | 34.10 |
| Relative Strength Index (RSI) | 55.33 |
| Average Volume (20 Days) | 1,579,571 |
Short Selling Information
The latest short interest is 13.54 million, so 14.27% of the outstanding shares have been sold short.
| Short Interest | 13.54M |
| Short Previous Month | 12.44M |
| Short % of Shares Out | 14.27% |
| Short % of Float | 15.43% |
| Short Ratio (days to cover) | 9.17 |
Income Statement
In the last 12 months, CRNX had revenue of $1.54 million and -$423.10 million in losses. Loss per share was -$4.54.
| Revenue | 1.54M |
| Gross Profit | -312.04M |
| Operating Income | -477.85M |
| Pretax Income | -423.10M |
| Net Income | -423.10M |
| EBITDA | -474.16M |
| EBIT | -477.85M |
| Loss Per Share | -$4.54 |
Full Income StatementBalance Sheet
The company has $1.09 billion in cash and $49.14 million in debt, giving a net cash position of $1.04 billion or $10.99 per share.
| Cash & Cash Equivalents | 1.09B |
| Total Debt | 49.14M |
| Net Cash | 1.04B |
| Net Cash Per Share | $10.99 |
| Equity (Book Value) | 1.07B |
| Book Value Per Share | 11.34 |
| Working Capital | 1.05B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$347.67 million and capital expenditures -$6.33 million, giving a free cash flow of -$354.00 million.
| Operating Cash Flow | -347.67M |
| Capital Expenditures | -6.33M |
| Free Cash Flow | -354.00M |
| FCF Per Share | -$3.73 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -31,130.16% |
| Pretax Margin | -27,563.32% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CRNX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -24.75% |
| Shareholder Yield | -24.75% |
| Earnings Yield | -10.25% |
| FCF Yield | -8.57% |
Analyst Forecast
The average price target for CRNX is $71.00, which is 63.14% higher than the current price. The consensus rating is "Buy".
| Price Target | $71.00 |
| Price Target Difference | 63.14% |
| Analyst Consensus | Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (5Y) | 310.70% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CRNX has an Altman Z-Score of 15.73 and a Piotroski F-Score of 3.
| Altman Z-Score | 15.73 |
| Piotroski F-Score | 3 |
